Previous studies demonstrated that ex vivo IL-2-activated PBSC could generate cytotoxic effectors without impairing haematopoietic reconstitution. Clinical experience and previous studies indicated that children with solid tumours could benefit from high-dose chemotherapy with immune modulation. We studied the generation of cytotoxic effectors from growth-factor ؎ chemotherapy-mobilised PBSC from 10 patients (five adults and five children) with different solid tumours. Cells were placed in culture in serum-free culture medium supplemented with IL-2 1000 U/ml ؎ IL-12 for 1, 2, 4 or 7 days. Anti-tumour cytotoxicity was tested against K562, Daudi and two neuroblastoma cell lines (Gau, NB91). Cultured adult PBSC in the presence of IL-2 (1000 U/ml) showed marked cytotoxicity against all the cell lines tested from day 1. At day 2, with an E:T ratio of 25:1, cytotoxicity was 53% ؎ 10.4, 63.2% ؎ 23.8, 38% ؎ 9.1, and 39% ؎ 15.7 against K562, Daudi, Gau and NB91, respectively. Cytotoxic activity of child PBSC was significantly lower (P Ͻ 0.05) and was displayed after longer culture times (day 4). No difference was found in the phenotype analysis of lymphoid subsets before and after IL-2 activation between adult and child PBSC. Haematological properties of the graft were not significantly impaired by IL-2 activation. Bone Marrow Transplantation (2001) 27, 869-875. Keywords: PBSC; interleukin 2; neuroblastoma; children High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) has been demonstrated to improve the prognosis of various solid tumours in children.
excessive visceral toxicity, other strategies must be devised to eradicate residual disease.
Post-transplant immunotherapy using ex vivo-activated PBSC in combination with HDC may constitute an effective strategy for improving clinical outcome without the drawback of overlapping toxicities. Interleukin-2 (IL-2) therapy instituted immediately after IL-2-activated autologous stem cell transplantation (ASCT) proved effective in inducing graft-versus-leukaemia (GVL) effects in an acute myeloid leukaemia (AML) murine model. 5 This therapeutic approach was attempted in autologous bone marrow (ABM) and then in PBSC collected from cancer patients. The latter study demonstrated that ex vivo IL-2-activated PBSC could generate cytotoxic effectors without impairing haematopoietic reconstitution. 6 The early administration of low-dose IL-2 after transplantation of IL-2-activated PBSC was then demonstrated to be feasible in women with poor risk breast cancer. [7] [8] [9] In the light of these preliminary results we felt that children with solid tumours could benefit from HDC combined with immune modulation. The occurrence of spontaneous regressions, 10 intratumour lymphocyte infiltrates with T cell clonal expansion, 11 and the potential efficacy of immunotherapy 12 all argue in favour of a possible role of the immune system in the fight against neuroblastoma (NB), the most common paediatric tumour. In vitro, NB cells are susceptible to NK lysis. 13, 14 Moreover, activation of peripheral blood mononuclear cells (PBMC) by IL-2 and interleukin-12 (IL-12) was shown to enhance NK-mediated lysis of NB cell lines. 15 These observations led us to examine the capacity of chemotherapy and/or growth factor-mobilised PBSC to generate cytotoxic effectors in vitro.
The present study was designed to evaluate the feasibility of generating cytotoxic effectors from mobilised PBSC in clinical grade culture conditions using IL-2 Ϯ IL-12. The ex vivo activation protocol was first validated in adult PBSC and then applied to PBSC from children with advanced cancers.
We studied the potential benefits of adding IL-12 to IL-2 in PBSC cultures and evaluated various culture times. The effects of cultures on the number and function of progenitor cells were also analysed.
Patients and methods

Patients and PBSC collection
PBSC were obtained from 10 cancer patients, five adults and five children whose clinical characteristics are summarised in Table 1 . All patients received G-CSF before PBSC collection. It was administered at a dose of 5 g/kg/day when PBSC were mobilised by both chemotherapy (Table  1) and G-CSF and at a dose of 10 g/kg/day when PBSC collection was performed in steady-state. Cytaphereses for PBSC collection were performed on a 4.0 COBE Spectra cell separator with anticoagulant citrate dextrose formula A (ACD-A) (COBE, Colombes, France) with a 1000 separation factor.
Cryopreservation, thawing and washing procedures
The cryopreservation solution (20% DMSO in 4% human serum albumin, HSA LFB, Les Ulis, France) was prepared and cooled to 4°C. An equal volume was added to the cells and the mixture (100-150 ml) was placed in freezing bags (Gambro Hemofreeze bag DF 700; Heckingen, Germany). Freezing was performed in a freezer programmed at a cooling rate of Ϫ1°C/min to Ϫ50°C and Ϫ5°C/min from Ϫ50°C to Ϫ180°C. The frozen cells were then stored in liquid nitrogen until use. On the day of culture, frozen PBSC were thawed rapidly in a 40°C waterbath. Each volume of the thawed cell suspension was diluted over a 10 min period with two volumes of cold (4°C) 2% HSA. The diluted PBSC were transferred into 600 ml blood bags and centrifuged at 650 g for 10 min at 10°C. The supernatant was discarded and the cells were resuspended in 4% HSA.
Quality control
Samples were analysed before and after culture. Quality control procedures for all products included total nucleated Ϫ4 m 2-mercaptoethanol, 2 mm l-glutamine, 10% agar leukocyte conditioned medium and 3 U/ml human recombinant erythropoietin. Cells were plated in triplicate in 35-mm plastic culture dishes at densities of 1 ϫ 10 3 /ml and 0.5 ϫ 10 3 /ml. Culture dishes were maintained at 37°C in 100% humidified air with 5% CO 2 . Colonies containing more than 50 cells were scored after incubation for 14 days.
PBSC cultures
Aliquots of 2 ϫ 10 8 cryopreserved nucleated cells (in 1 ml) were diluted in 9 ml of X-vivo 10 medium (Biowhittaker, Bohringer, Germany) and cultured in 25 cm 2 tissue culture flasks (Nunc, Oslo, Denmark, final density, 2 ϫ 10 7 /ml). Human recombinant IL-2 (provided by Chiron, Ratingen, The Netherlands) was added at the beginning of the culture at a concentration of 1000 units/ml. All flasks were placed in a humidified incubator with 5% CO 2 and maintained at 37°C for 7 days. On days 2, 4 and 7, supernatant cells were harvested and adherent cells were detached by scraping with a rubber policeman. Cells were then pooled and washed in PBS (phosphate-buffered saline without Ca ϩϩ or Mg ϩϩ ; Gibco BRL, Paisley, UK) before testing.
Cytotoxicity assay
The cytolytic activity of cultured PBSC against the NKsensitive K562 and NK-resistant Daudi cell line targets was measured at days 0, 2, 4 and 7 in a standard 4-h
51
Cr release assay (using triplicate cultures). In addition, lytic activity was tested against the two neuroblastoma cell lines, IGR-NB91 and -GAU.
Briefly, targets cells (10 6 ) were labelled with 150 Ci Na 2 51 Cr O 4 (1 mCi/ml; Dupont, Boston, MA, USA) for 1 h at 37°C. All determinations were performed in triplicate and data were calculated as means Ϯ standard deviation (s.d.).
Phenotype analysis
Lymphocyte subpopulations among PBSC were characterised using fluorescein (FITC)-or phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs) directed against CD3, CD4, CD8, CD25, CD56, CD69, HLA-DR, all purchased from Becton Dickinson (BD, Mountain View, CA, USA). Briefly two-colour immunostainings were performed by incubating 5 ϫ 10 5 PBSC for 20 min at 4°C with mAbs, washed twice in cold phosphate-buffered saline ((PBS), GibcoBRL, Paisley, UK) containing 2% fetal calf serum and fixed with 2% formaldehyde-PBS. Labelled (FITCIgG1/PE-IgG2a, Simultest; BD) isotype-matched antibodies were used as negative controls. Stained samples were acquired using a FACSCalibur flow cytometer (BDIS). Viable cells (5 × 10 3 ) were gated on lymphocyte forward/side scatter (FSC/SSC) criteria and analysed using the CellQuest software (BD).
Statistical analysis
Results are presented as means Ϯ s.d. Groups were compared using the Student's t-test.
Results
Thirteen thawed PBSC suspensions obtained from 10 cancer patients (five adults and five children) were cultured in clinical grade conditions with IL-2 (1000 IU/ml) Ϯ IL-12 (4 IU/ml) and analysed at days 0, 2, 4 and in some cases at day 7. For each experiment, a cytokine-free PBSC culture was also performed as a control.
Recovery of progenitor cells and colony-forming units
No difference was observed in recovery of haematopoietic cells in culture between cultured adult and child PBSC.
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Results were then pooled. Table 2 shows the recovery of nucleated cells, CD34 ϩ cells and colony-forming units (CFU-GM and BFU-E). Compared to day 0 values, a significant drop was observed in nucleated and CD34 ϩ cell percentages after 2 days of culture, whatever the culture conditions. Prolonging the culture did not deplete cells further, even after a 7 day culture (data not shown). When PBSC were cultured with IL-2, the percentage of CD34 ϩ progenitor cells increased with the duration of the culture. On day 4, a significantly higher number of CD34 ϩ cells were present in IL-2 when compared to control cultures (P Ͻ 0.02). This difference was also observed when IL-12 was added to IL-2. The mean recovery of CFU-GM was of borderline significance after 4 days of culture with IL-2 (1000 U/ml): 70.8% (s.
Cytotoxicity of IL-2 ± IL-12-stimulated cultures
Cultured adult PBSC maintained in the presence of IL-2 (1000 U/ml) showed marked cytotoxicity against both NKsensitive K562 and NK-resistant Daudi cell line targets with an E:T ratio of 25:1. Results are presented in Table  3 . Cytotoxic activity remained high even at a low E:T ratio, as shown with a representative experiment in patient 5 ( Figure 1a) . In addition to the lysis of classic targets, significant cytotoxicity was exhibited against the two neuroblastoma cell lines. For most experiments with adult cells, cytotoxic activity was observed as early as day 1, was maximal on day 2 and remained stable with no further enhancement in prolonged cultures. Few experiments were performed with the addition of IL-12 (4 U/ml) to IL-2 (1000 U/ml) in adult PBSC, but no increased lysis was observed, whatever the culture duration and the targets tested (data not shown). Overall, cytotoxic activity of child PBSC was significantly lower than that displayed by adult PBSC (P Ͻ 0.05). However, the cytotoxicity measured was heterogeneous with results varying from one child PBSC culture to another. As shown in Figure 1b , high cytotoxicity was observed in patient No. 6, even at an E:T ratio of 25:1, after a 4-day IL-2 culture (1000 U/ml). In contrast, in patient No. 10, significant cytolytic activity was observed after 4 days of culture only against K562 at a high E:T ratio of 50:1 (21%) (data not shown). Activation appeared later in most child PBSC when compared with adult PBSC. For example, in patient No. 6, no cytotoxic effect was displayed after culture with IL-2 (1000 U/ml) at days 1 and 2, but began to be observed after 3 days of culture (29% against K562, E:T ratio 25/1) and increased at day 4 (48% with the same experimental conditions). As in adult PBSC cultures, adding IL-12 to IL-2 cultures did not increase lysis significantly (data not shown).
Phenotype analysis of lymphoid cells
Lymphoid cells in the cultures with IL-2 (1000 U/ml) were analysed to determine the membrane phenotype. Activation status antigens were studied in lymphoid cells in child PBSC cultures. As shown in Table 3 , no marked changes were observed in the relative proportion of lymphocytes on Data shown concern nucleated and CD34 ϩ cell recovery and colony-forming unit activity of previously frozen PBSC after culture with or without IL-2 (1000 U/ml) Ϯ IL-12 (4 U/ml). Results are expressed as mean percentages (Ϯ s.d.) of day 0 values. Among the activation markers (CD25, CD56, CD69, HLA-DR molecules), whose expression was evaluated on CD3 ϩ T cell subpopulations, only CD69 and HLA-DR antigens were up-regulated in child PBSC cultures at day 4 ( Table 4 ). The increased percentage of CD3 ϩ DR ϩ cells was of borderline significance (P = 0.07).
Discussion
After transplantation, an immune anti-tumour effect appears to be linked to the presence of lymphoid effectors in the graft and to the maintenance of their cytotoxic activity during the early post-transplant period. In a murine model of AML, IL-2 therapy instituted immediately after IL-2 activated BMT was the strategy which best induced a GVL effect that cured mice. 5, 16 In this model, deferring the administration of IL-2 seemed to compromise survival. The crucial importance of the early post-transplantation period has also been demonstrated in humans. 17 The use of an IL-2 receptor antibody as GVH prophylaxis from day 1 to day 28 after an allogeneic transplantation delayed but did not decrease the incidence of GVHD. It also increased the relapse rate which was similar to that observed after T celldepleted allogeneic transplantation. The demonstration that marked cytotoxicity could be obtained against both NKsensitive (K562) and NK-resistant (Daudi) cell targets by activating PBSC with IL-2 18 logically prompted the evaluation of the feasibility of an IL-2-activated graft. Two clinical studies in women with poor risk breast cancer demonstrated the cytotoxic activity of mobilised PBSC. [7] [8] [9] The prognosis of stage 4 neuroblastoma has improved significantly with high-dose chemotherapy combined or not with TBI and ASCT as consolidation therapy 1,2 but remains poor. The respective role of autograft contamination by tumour cells and of persistent minimal residual disease is not clear. Comparable disease-free survival rates were observed after consolidation strategies using similar consolidation regimens followed by purged or unpurged ABMT. 19, 20 No benefits have been evidenced with allogeneic BMT in neuroblastoma patients. 21, 22 The gene-mark- 
Lymphoid cell subsets were analysed in PBSC at collection and 4 days after the initiation of cultures with IL-2 (1000 U/ml) by dual-colour flow cytometric analysis. Results are expressed as the median % (min-max) of positive gated lymphoid cells.
Bone Marrow Transplantation ing study published by Rill et al 3 appears to attribute a major role to contaminating cells. Whatever the cause of relapses, strategies aimed at both purging the graft and inducing a 'GVT' effect could potentially improve the prognosis in these children.
Two points had to be validated before developing strategies using activated grafts followed by the early administration of IL-2 in vivo in patients with stage 4 neuroblastoma. First, we had to prove that PBSC were capable of generating effectors against neuroblastoma cell lines and then evaluate the immune properties of activated child PBSC.
In the present series, marked cytotoxicity against NK sensitive/resistant cell targets was observed in adult PBSC cultured with IL-2. Significant cytotolytic activity was also obtained against the two neuroblastoma cell lines tested. Neuroblastoma cell lines are known to be sensitive to NK cell cytotoxicity, albeit to a variable extent. 13, 23 High-dose IL-2 (1000 IU/ml) cultures appear to be the most effective way of obtaining efficient lysis of NK-sensitive/resistant and neuroblastoma cell line targets. IL-12 alone was demonstrated to induce only weak cytotoxicity but it enhanced NK cell-mediated cytotoxicity when it was added to IL-2 (100 U/ml). 15 The benefits of adding IL-12 to IL-2 to activate human bone marrow-derived effectors, were only demonstrated when IL-2 was used at a low or intermediate dose. 24, 25 In our study, enhanced lysis of NKsensitive/resistant targets related to the addition of IL-12 was only observed when low doses of IL-2 (10 or 100 IU/ml) were used (data not shown); cytotoxicity was not improved in PBSC activated with high-dose IL-2 (1000 U/ml). Cytotoxic activity could only be obtained in child PBSC after longer cultures (at least 3 days). However, it was more heterogeneous and lower than that observed with adult PBSC. The phenotype analysis did not reveal any significant difference in the distribution of lymphoid subsets between adult and child PBSC either before or after activation. Phenotype changes apparently do not explain the decreased activity observed in children compared to adults. Although G-CSF has been reported to impair NK cell functions and to decrease NK progenitors in G-CSF-mobilised collections, 26 the mobilising protocol cannot be incriminated in the impaired immune function in child PBSC since PBSC were mobilised with G-CSF in both adults and children. On the other hand, children had previously received a longer treatment with conventional chemotherapy than adults before PBSC collection. These conventional chemotherapy courses were often followed by the administration of G-CSF. The respective role of prolonged chemotherapy and of the repeated administration of G-CSF in the impairment of the immune function of IL-2-activated child PBSC remains to be explored in further studies. In a murine model, the cytotoxic activity of in vitro IL-2-activated PBSC was studied after mobilisation with G-CSF associated or not with cyclophosphamide and/or IL-2. The in vivo administration of IL-2 with the mobilising regimen was demonstrated to prevent the loss of cytotoxicity associated with the use of cyclophosphamide. 27 Although the use of IL-2 in the mobilising regimen could help to improve the immune activation of the graft, strategies are explored to avoid the toxicity related to the repeated in vivo IL-2 administration.
The toxicity of IL-2-activated ABM or PBSC is reported to be substantially decreased after freezing and thawing. 16 Like others, we developed a strategy for culturing thawed PBSC in IL-2 and we evaluated their haematopoietic capacities. In most studies, IL-2 activation of PBSC did not impair long-term haematopoiesis. 28, 29 In the present study, about 50% of nucleated cells were recovered after 2 day cultures, whatever the culture conditions and this drop did not worsen when cultures were prolonged. Among the 50% of nucleated cells lost were cells that had sustained lethal damage through freezing/thawing, but whose status allowed them to be counted and placed in culture.
As already observed, 28 the percentage of CD34 ϩ cells increased in IL-2-cultured PBSC when compared to controls. This percentage increased when cultures were prolonged and a significant difference was observed in 4 day old cultures. The number of CFU-GM increased in IL-2-activated PBSC although the difference was of borderline significance. This beneficial effect on haematopoietic progenitor cell content could be due to myeloid growth factors secreted by activated lymphocytes and NK cells. 30 On the other hand, no difference was observed in BFU-E recovery, whatever the culture conditions. This study demonstrates that mobilised, previously frozen and thawed, adult PBSC activated by IL-2 (1000 U/ml) are capable of generating high cytotoxicity against NK-sensitive/resistant and neuroblastoma cell line targets without impairing the recovery of haematopoietic cells in culture. Such results were not constantly obtained in child PBSC which exhibited, despite the low number of children samples studied, significantly reduced cytotoxic activities compared to their adult counterparts. An on-going study is evaluating the benefits of prolonging cultures of PBSC collected from children with stage 4 neuroblastoma. As optimal activation conditions will be established for child PBSC, a clinical trial will be conducted in children with poor-risk stage 4 neuroblastoma using such activated grafts followed by immediate administration of IL-2 in vivo.
